Literature DB >> 11798188

Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator.

Hiroaki Kataoka1, Hiroshi Itoh, Yoshitsugu Nuki, Ryouichi Hamasuna, Seiji Naganuma, Naomi Kitamura, Takeshi Shimomura.   

Abstract

Hepatocyte growth factor activator inhibitor type 2 (HAI-2) is a serine proteinase inhibitor containing two Kunitz-type inhibitor domains, initially identified as a potent inhibitor of hepatocyte growth factor activator (HGFA). In a previous study (Biochem. Biophys. Res. Commun. 255, 740-748, 1999), we reported that a predominant transcript of mouse HAI-2 is a splicing variant lacking the first Kunitz domain (KD-1). Since KD-1 was reported to be responsible for the inhibition of HGFA in human HAI-2 and the second Kunitz domain (KD-2) of human HAI-2 was much less inhibitory against HGFA, it has been suggested that most of mouse HAI-2 may be ineffective in inhibiting HGFA. In this study, we have performed functional characterization of Kunitz domains in mouse HAI-2 by using recombinant proteins synthesized by Chinese hamster ovary cells without or with point mutation in the putative reactive site of each Kunitz domain. The results revealed that, unlike human HAI-2, KD-2 of mouse HAI-2 efficiently inhibits HGFA. Therefore, the major mouse HAI-2 protein that consists only of KD-2 can be a potent inhibitor of HGF activation in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11798188     DOI: 10.1006/bbrc.2001.6313

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Nuclear translocation of H2RSP is impaired in regenerating intestinal epithelial cells of murine colitis model.

Authors:  Seiji Naganuma; Hiroshi Itoh; Shuichiro Uchiyama; Koki Nagaike; Hiroyuki Tanaka; Yutaka Akiyama; Kazuo Chijiiwa; Hiroaki Kataoka
Journal:  Virchows Arch       Date:  2005-09-28       Impact factor: 4.064

Review 2.  Roles of hepatocyte growth factor activator (HGFA) and its inhibitor HAI-1 in the regeneration of injured gastrointestinal mucosa.

Authors:  Hiroshi Itoh; Hiroaki Kataoka
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

3.  Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses.

Authors:  Wataru Komaki; Tsuyoshi Fukushima; Hiroyuki Tanaka; Hiroshi Itoh; Etsuo Chosa; Hiroaki Kataoka
Journal:  Virchows Arch       Date:  2008-09-04       Impact factor: 4.064

4.  Roles of Kunitz domains in the anti-invasive effect of hepatocyte growth factor activator inhibitor type 1 in human glioblastoma cells.

Authors:  Shiro Miyata; Tsuyoshi Fukushima; Kazuyo Kohama; Hiroyuki Tanaka; Hideo Takeshima; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2007-11       Impact factor: 4.174

Review 5.  Mechanisms of hepatocyte growth factor activation in cancer tissues.

Authors:  Makiko Kawaguchi; Hiroaki Kataoka
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

6.  Hepatocyte growth factor activator inhibitor-2 stabilizes Epcam and maintains epithelial organization in the mouse intestine.

Authors:  Makiko Kawaguchi; Koji Yamamoto; Naoki Takeda; Tsuyoshi Fukushima; Fumiki Yamashita; Katsuaki Sato; Kenichiro Kitamura; Yoshitaka Hippo; James W Janetka; Hiroaki Kataoka
Journal:  Commun Biol       Date:  2019-01-04

7.  Hepatocyte growth factor activator inhibitor-1 is induced by bone morphogenetic proteins and regulates proliferation and cell fate of neural progenitor cells.

Authors:  Raili Koivuniemi; Johanna Mäkelä; Marie-Estelle Hokkanen; Céline Bruelle; Tho Huu Ho; Roxana Ola; Laura Korhonen; Jim Schröder; Hiroaki Kataoka; Dan Lindholm
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

8.  Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma.

Authors:  Soonyean Hwang; Hye-Eun Kim; Michelle Min; Rekha Raghunathan; Izabela P Panova; Ruchi Munshi; Byungwoo Ryu
Journal:  J Invest Dermatol       Date:  2015-04-24       Impact factor: 8.551

Review 9.  Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.

Authors:  Shoichiro Mukai; Koji Yamasaki; Masato Fujii; Takahiro Nagai; Naoki Terada; Hiroaki Kataoka; Toshiyuki Kamoto
Journal:  Int J Mol Sci       Date:  2020-04-11       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.